Hubbry Logo
1,4-Butanediol1,4-ButanediolMain
Open search
1,4-Butanediol
Community hub
1,4-Butanediol
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
1,4-Butanediol
1,4-Butanediol
1,4-Butanediol
View on Wikipedia
from Wikipedia

1,4-Butanediol
Names
Preferred IUPAC name
Butane-1,4-diol
Other names
Tetramethylene glycol
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.003.443 Edit this at Wikidata
EC Number
  • 203-786-5
RTECS number
  • EK0525000
UNII
  • InChI=1S/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2 checkY
    Key: WERYXYBDKMZEQL-UHFFFAOYSA-N checkY
  • InChI=1/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2
  • OCCCCO
  • C(CCO)CO
Properties[1][2]
C4H10O2
Molar mass 90.122 g·mol−1
Density 1.0171 g/cm3 (20 °C)
Melting point 20.1 °C (68.2 °F; 293.2 K)
Boiling point 235 °C (455 °F; 508 K)
Miscible
Solubility in ethanol Soluble
−61.5·10−6 cm3/mol
1.4460 (20 °C)
Hazards[3][4]
GHS labelling:
Acute Tox. (oral) 4
Warning
H302, H336
P261, P264, P270, P271, P301+P312, P304+P340, P312, P330, P403+P233, P405, P501
NFPA 704 (fire diamond)
NFPA 704 four-colored diamondHealth 1: Exposure would cause irritation but only minor residual injury. E.g. turpentineFlammability 1: Must be pre-heated before ignition can occur. Flash point over 93 °C (200 °F). E.g. canola oilInstability 0: Normally stable, even under fire exposure conditions, and is not reactive with water. E.g. liquid nitrogenSpecial hazards (white): no code
1
1
0
Flash point (open cup) 121 °C (250 °F; 394 K)
350 °C (662 °F; 623 K)
Related compounds
Related butanediols
 1,2-Butanediol
1,3-Butanediol
2,3-Butanediol
cis-Butene-1,4-diol
Related compounds
 Succinaldehyde
Succinic acid
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

1,4-Butanediol, also called Butane-1,4-diol (other names include 1,4-B, BD, BDO, and 1,4-BD),[5] is a primary alcohol and an organic compound with the formula HOCH2CH2CH2CH2OH. It is a colorless viscous liquid first synthesized in 1890 via acidic hydrolysis of N,N'-dinitro-1,4-butanediamine by Dutch chemist Pieter Johannes Dekkers, who called it "tetramethylene glycol".[6][7]

Synthesis

[edit]
Conversion of butane to butanediol or butyrolactone via oxidation to maleic anhydride followed by hydrogenation over copper chromite.[8]

In one industrial chemical synthesis, acetylene reacts with two equivalents of formaldehyde to form butyne-1,4-diol. Hydrogenation of butyne-1,4-diol gives butane-1,4-diol.[9] It is also made on an industrial scale from maleic anhydride in the Davy process, which is first converted to the methyl maleate ester, then hydrogenated. Other routes are from butadiene, allyl acetate and succinic acid.

A biological route to BD has been commercialized that uses a genetically modified organism.[10] The biosynthesis proceeds via 4-hydroxybutyrate.

Industrial use

[edit]

Butane-1,4-diol is used industrially as a solvent[additional citation(s) needed] and in the manufacture of some types of plastics, elastic fibers and polyurethanes. In organic chemistry, 1,4-butanediol is used for the synthesis of γ-butyrolactone (GBL). In the presence of phosphoric acid and high temperature, it dehydrates to the important solvent tetrahydrofuran.[11] At about 200 °C in the presence of soluble ruthenium catalysts, the diol undergoes dehydrogenation to form butyrolactone.[12] It is used to synthesize 1,4-butanediol diglycidyl ether which is then used as a reactive diluent for epoxy resins.[13]

1,4-Butanediol is used in the production of polybutylene terephthalate (PBT) plastic.[14]

World production of butane-1,4-diol was claimed to be about one million metric tons per year and market price is about US$2,000 (€1,600) per ton in 2005. In 2013, worldwide production was claimed to be billions of pounds (consistent with approximately one million metric tons).[15]

Almost half of it is dehydrated to tetrahydrofuran to make fibers such as Spandex.[16] The largest producer is BASF.[17]

Use as a recreational drug

[edit]
FDA warning against products containing GHB and its prodrugs, such as butane-1,4-diol.

Butane-1,4-diol is also used as a recreational drug known by some users as "Bute",[18] "One Comma Four", "Liquid Fantasy", "One Four Bee" or "One Four B-D-O".

Some federal courts in the USA have stated that 1,4-butanediol exerts effects similar to its metabolite, GABA analogue gamma-hydroxybutyrate (GHB), but several other federal courts have ruled that it does not.

1,4-butenediol (CAS 110-64-5) may be incorrectly sold as 1,4-butanediol but should not be confused with it.

Pharmacokinetics

[edit]

Butane-1,4-diol is rapidly converted into GHB acid by the enzymes alcohol dehydrogenase and aldehyde dehydrogenase, and differing levels of these enzymes may account for differences in effects and side effects between users.[19] While co-administration of ethanol and GHB already poses serious risks, co-administration of ethanol with 1,4-butanediol will interact considerably and has many other potential risks. This is because the same enzymes that are responsible for metabolizing alcohol also metabolize 1,4-butanediol so there is a strong chance of a dangerous drug interaction.[19][20] Emergency room patients who overdose on both ethanol and 1,4-butanediol often present with symptoms of alcohol intoxication initially and as the ethanol is metabolized the 1,4-butanediol is then able to better compete for the enzyme and a second period of intoxication ensues as the 1,4-butanediol is converted into GHB.[19]

Metabolic pathway of butane-1,4-diol, γ-butyrolactone and γ-hydroxybutyric acid (GHB).

Pharmacodynamics

[edit]

Butane-1,4-diol seems to have two types of pharmacological actions. The major psychoactive effects of 1,4-butanediol are because it is metabolized into GHB; however there is a study suggesting that 1,4-butanediol may have potential alcohol-like pharmacological effects on its own.[20] The study arrived at this conclusion based on the finding that butane-1,4-diol coadministered with ethanol led to potentiation of some of the behavioral effects of ethanol. However, potentiation of ethanol's effects may simply be caused by competition for the alcohol dehydrogenase and aldehyde dehydrogenase enzymes with co-administered 1,4-butanediol. The shared metabolic rate-limiting steps thus leads to slowed metabolism and clearance for both compounds including ethanol's known toxic metabolite acetaldehyde.

Another study found no effect following intracerebroventricular injection of butane-1,4-diol in rats.[21] This contradicts the hypothesis of butane-1,4-diol having inherent alcohol-like pharmacological effects.

Like gamma-hydroxybutyric acid, butane-1,4-diol is safe only in small amounts. Adverse effects in higher doses include nausea, vomiting, dizziness, sedation, vertigo, and potentially death if ingested in large amounts. Anxiolytic effects are diminished and side effects increased when used in combination with alcohol.

Legality

[edit]

While butane-1,4-diol is not currently scheduled federally in the United States,[22] a number of states have classified 1,4-butanediol as a controlled substance. Individuals have been prosecuted for possession of 1,4-butanediol under the Federal Analog Act as substantially similar to GHB.[23] A federal case in New York in 2002 ruled that 1,4-butanediol could not be considered an analog of GHB under federal law,[24] but that decision was later overturned by the Second Circuit.[25] A jury in Federal District Court in Chicago found that 1,4-butanediol was not an analog of GHB under federal law, which was not disputed on the case's appeal to the Seventh Circuit Court of Appeals, however this finding did not affect the outcome of the case.[26] In the United Kingdom, 1,4-butanediol was scheduled in December 2009 (along with another GHB precursor, gamma-butyrolactone) as a Class C controlled substance. In Germany, the drug is not explicitly illegal, but might also be treated as illegal if used as a drug. It is controlled as a Schedule VI precursor in Canada.

2007 contamination of Bindeez toy

[edit]
See also: Bindeez

A toy called "Bindeez" ("Aqua Dots" in North America) was recalled by the distributor in November 2007 because of the presence of butane-1,4-diol. The toy consists of small beads that stick to each other by sprinkling water. Butane-1,4-diol was detected by GC-MS.[27] The production plant seems to have intended to cut costs by replacing less toxic pentane-1,5-diol with butane-1,4-diol. ChemNet China listed the price of butane-1,4-diol at between about US$1,350–2,800 per metric ton, while the price for 1,5-pentanediol is about US$9,700 per metric ton.[28]

2021 poisoning at Darmstadt Technical University

[edit]

In August 2021, several people fell severely ill after consuming drinks at building L2.01 at the Lichtwiese Campus of Darmstadt Technical University, Germany. Seven showed severe symptoms, two were transported to a hospital in Frankfurt am Main, and a 30-year-old person was, for a time, in a critical state. Butane-1,4-diol had been detected in milk packages, as well as in water filters. At the location, detectives also found bromophenols and dicyclohexylamine.[29]

Derivatives

[edit]

A variety of 1,4-butanediol derivatives are GHB-like drugs or GHB receptor agonists. These include GHB itself, γ-butyrolactone (GBL), aceburic acid, ethyl acetoxy butanoate (EAB), Γ-crotonolactone, γ-hydroxybutyraldehyde, γ-hydroxyvaleric acid (GHV), γ-valerolactone, γ-hydroxycrotonic acid (GHC or T-HCA), and 4-hydroxy-4-methylpentanoic acid (UMB68), among others. An analogue that is not a 1,4-butanediol derivative but is related and still shows affinity for the GHB receptor is 3-chloropropanoic acid (UMB66).

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

1,4-Butanediol

View on Grokipedia
from Grokipedia
1,4-Butanediol (BDO) is a straight-chain aliphatic diol with the molecular formula C₄H₁₀O₂ and the structural formula HO(CH₂)₄OH, appearing as a colorless, viscous, and water-miscible liquid with a boiling point of 230 °C and melting point of 20.1 °C. Industrially, it serves as a key commodity chemical, with global production exceeding 2.5 million metric tons annually, primarily employed as a precursor for synthesizing polymers such as polybutylene terephthalate (PBT), spandex fibers, and polyurethane elastomers, as well as for producing solvents like tetrahydrofuran (THF) and gamma-butyrolactone (GBL). In the human body, BDO undergoes rapid enzymatic conversion via alcohol dehydrogenase to gamma-hydroxybutyric acid (GHB), a neurotransmitter with sedative effects, which has prompted its diversion for recreational use despite severe risks including respiratory depression, coma, seizures, and fatalities. Due to this metabolic pathway and abuse potential, BDO is classified as a List I controlled chemical precursor in the United States, subject to strict regulatory oversight by the Drug Enforcement Administration to curb illicit GHB production. Its toxicity profile includes acute oral hazards (LD50 approximately 1.6 g/kg in rats) and central nervous system depression, underscoring the disconnect between its legitimate industrial value and public health concerns from misuse.

Physical and Chemical Properties

Molecular Structure and Formula


1,4-Butanediol, with the IUPAC name butane-1,4-diol, possesses the molecular formula C₄H₁₀O₂ and a molecular weight of 90.12 g/mol. The compound features a straight-chain aliphatic structure consisting of four methylene (–CH₂–) groups flanked by two primary hydroxyl (–OH) groups at the terminal positions, expressed structurally as HO(CH₂)₄OH or HOCH₂CH₂CH₂CH₂OH.
This linear diol configuration distinguishes 1,4-butanediol from its isomers, such as 1,3-butanediol or 2,3-butanediol, by enabling symmetrical hydrogen bonding and influencing its physical properties like viscosity and boiling point. The molecule's InChI representation is InChI=1S/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2, confirming its precise atomic connectivity.

Physical Characteristics

1,4-Butanediol is a colorless, viscous liquid at room temperature, often described as having a mild or faint odor. It exhibits hygroscopic properties, readily absorbing moisture from the air. The compound is fully miscible with water and soluble in common organic solvents including ethanol, methanol, acetone, and esters. Key thermophysical properties include a melting point of 20 °C and a boiling point of 228 °C at standard pressure. Its density is 1.02 g/cm³ relative to water at 20 °C, with absolute values reported around 1.017 g/mL at 25 °C. The low vapor pressure, below 0.1 hPa at 20 °C, indicates limited volatility under ambient conditions. Viscosity contributes to its handling characteristics, with dynamic viscosity approximately 71–83 mPa·s near room temperature, depending on exact conditions.
PropertyValueConditionsSource
Melting point20 °C-
Boiling point228–230 °C760 mmHg
Density1.017 g/mL25 °C
Vapor pressure<0.1 hPa20 °C

Chemical Reactivity

1,4-Butanediol exhibits reactivity primarily at its two terminal primary hydroxyl groups, enabling nucleophilic substitutions, oxidations, dehydrations, and condensations typical of aliphatic alcohols. These functional groups confer high reactivity toward electrophiles such as acid chlorides, anhydrides, and isocyanates, while also supporting elimination reactions under acidic conditions. The molecule's linear chain allows for intramolecular cyclizations, distinguishing it from shorter diols. It reacts vigorously with strong oxidizing agents, potentially forming carbonyl compounds or carboxylic acids, and is sensitive to heat and light, which may promote decomposition. A prominent reaction is the acid-catalyzed intramolecular dehydration to tetrahydrofuran (THF), proceeding via protonation of one hydroxyl group followed by nucleophilic attack from the other, with water elimination. This occurs efficiently over catalysts like strong acid cation exchange resins or Zr-Al mixed oxides at 200–360 °C, yielding up to 90% THF in vapor or liquid phases. Kinetic models indicate pseudo-first-order dependence on 1,4-butanediol concentration, with activation energies around 100–150 kJ/mol depending on the catalyst. Dehydrogenation to γ-butyrolactone (GBL) involves selective removal of hydrogen from the alcohol functions, forming a five-membered lactone ring, typically in gas phase over Cu-based catalysts at 150–300 °C. Mechanisms proceed via intermediate 4-hydroxybutanal hemiacetalization, achieving conversions exceeding 95% with near-quantitative selectivity under optimized conditions. Esterification with carboxylic acids, such as acrylic or terephthalic acid, forms mono- or diesters via Fischer-type mechanisms, often catalyzed by metallo-organics or enzymes; these proceed as consecutive reversible steps, with rate constants favoring diester formation at equimolar ratios. In polymerization, 1,4-butanediol condenses with diacids like terephthalic acid to yield polybutylene terephthalate (PBT) via transesterification-polycondensation, or with succinic acid for bio-based polybutylene succinate, requiring catalysts like titanium alkoxides at 200–250 °C under vacuum to remove byproducts. It also reacts with diisocyanates (e.g., MDI) to form polyurethane hard segments, where the diol acts as a chain extender, enhancing crystallinity and mechanical properties due to its linear structure. Halogenation or amination derivatives are accessible but less industrially prominent.

History and Production

Discovery and Early Development

1,4-Butanediol was first synthesized in 1890 by Dutch chemist Pieter Johannes Dekkers through the acidic hydrolysis of N,N'-dinitro-1,4-butanediamine. This laboratory preparation marked the initial isolation of the compound, originally referred to as tetramethylene glycol, yielding a colorless viscous liquid with the formula HO(CH₂)₄OH. Early industrial development occurred in the 1940s with the Reppe process, pioneered by Walter Reppe at BASF in Germany. The process involved the catalyzed reaction of acetylene and formaldehyde to form 1,4-butynediol, followed by selective hydrogenation to 1,4-butanediol, enabling scalable production despite the hazards of acetylene handling. BASF constructed a plant in Ludwigshafen in 1940 with an annual capacity of 20,000 metric tons, targeting applications in polymer precursors amid wartime demands for synthetic materials. Post-World War II, commercialization expanded to the United States, where General Aniline & Film (GAF) initiated the first dedicated 1,4-butanediol production facility in the 1950s, leveraging the Reppe route for growing industrial solvent and resin markets. This period established 1,4-butanediol as a key intermediate, though early processes faced challenges from acetylene's explosivity and reliance on coal-derived feedstocks.

Commercialization and Scale-Up

The Reppe process, involving the reaction of acetylene with formaldehyde to form 1,4-butynediol followed by hydrogenation, enabled the initial commercialization of 1,4-butanediol. In 1940, BASF established the first industrial-scale plant at Ludwigshafen, Germany, with an annual production capacity of 20,000 metric tons, targeting applications in polymers and fibers. This facility represented a significant scale-up from laboratory synthesis, leveraging high-pressure catalysis developed by Walter Reppe despite wartime constraints on raw materials like acetylene derived from calcium carbide. Post-World War II reconstruction and rising demand for tetrahydrofuran and polytetramethylene ether glycol drove further expansion of Reppe-based production, which accounted for over 95% of global output by 1984. However, the process's dependence on costly and energy-intensive acetylene prompted development of alternatives; the maleic anhydride hydrogenation route, licensed by Davy Process Technology, achieved commercial viability in the 1970s, offering lower costs through propylene-derived feedstocks. By the 1980s, acetylene scarcity and price volatility accelerated diversification, with Mitsubishi Chemical commercializing a butadiene-acetic acid esterification and hydrogenolysis process in Japan, marking the end of Reppe's production monopoly after over four decades. These shifts enabled global capacity to grow from tens of thousands of tons in the mid-20th century to approximately 2.5 million metric tons annually by the mid-2020s, supported by investments in Asia-Pacific facilities amid surging electronics and automotive sectors. Global production capacity for 1,4-butanediol (BDO) stood at approximately 4,000 kilotons in 2024, with projections for expansion to 5,300 kilotons by 2034, driven by investments in new facilities amid rising demand for downstream polymers. Leading producers include BASF SE, which held about 21% of global supply in 2023, followed by LyondellBasell Industries Holdings B.V., Mitsubishi Chemical Group Corporation, Nan Ya Plastics Corporation, and Huntsman Corporation, with the latter maintaining over 650 kilotons of capacity. Asia-Pacific, particularly China, dominates production, accounting for the majority of output due to cost advantages and proximity to key markets. Market volume reached 3.665 million tonnes in 2024, expected to grow to 6.189 million tonnes by 2035 at a compound annual growth rate (CAGR) of 4.94%, reflecting steady demand from sectors like textiles and electronics. In value terms, the global market was valued at USD 7.68 billion in 2024, forecasted to reach USD 13.41 billion by 2030 with a CAGR of around 7-8%, though estimates vary due to fluctuating raw material costs and regional pricing dynamics. Primary growth drivers include expanding applications in polybutylene terephthalate (PBT) resins for automotive components, spandex fibers for apparel, and biodegradable plastics like polybutylene adipate terephthalate (PBAT), with bio-based BDO variants gaining traction amid sustainability pressures. Pricing trends showed volatility in 2024, with a 5.23% decline to USD 1,105 per metric ton in China's Q3 market due to oversupply and subdued downstream demand, contrasting an earlier Q1 uptrend in Asia from elevated production costs. In 2025, major producers like BASF announced price increases, such as $0.08/lb for BDO in March in the US and Canada, amid ongoing supply pressures. Investments in capacity, such as a new 120,000-tonne-per-year plant launched in 2024 and over USD 400 million in bio-BDO projects, signal confidence in long-term expansion despite potential supply chain risks from petrochemical feedstock dependencies. Regional shifts favor Asia's dominance, with North America and Europe focusing on high-value, specialty applications to offset import reliance.

Synthesis Methods

Traditional Industrial Routes

The Reppe process, developed by Walter Reppe at BASF in the 1940s, represents one of the earliest and historically dominant methods for industrial 1,4-butanediol (BDO) production, relying on acetylene derived from coal or natural gas and formaldehyde from methanol oxidation. In this two-step route, acetylene reacts with formaldehyde in the presence of a copper-bismuth catalyst at elevated temperatures (around 100–120°C) and pressures (1–2 MPa) to form 1,4-butynediol, which is then hydrogenated over a nickel or palladium catalyst under high pressure (up to 20 MPa) and temperature (up to 150°C) to yield BDO. This process achieved commercial scale in the 1950s and accounted for over 95% of global BDO production as late as 1984, though it is energy-intensive due to acetylene handling and has largely been phased out in favor of cheaper alternatives amid rising natural gas costs. Another established route involves the hydrogenation of maleic anhydride, often via the Davy process licensed by Johnson Matthey Davy Technologies, starting from n-butane oxidation to maleic anhydride followed by esterification to dialkyl succinates (e.g., dimethyl succinate) and subsequent hydrogenolysis over copper-based catalysts. The process typically operates in two stages: esterification of maleic anhydride with methanol at 150–200°C, producing succinate esters, then high-pressure hydrogenation (10–30 MPa, 200–250°C) using catalysts like Cu/ZnO or Cu/Cr to achieve BDO yields exceeding 90%, with gamma-butyrolactone as a key intermediate. Commercialized in the 1980s, this method benefits from integrated maleic anhydride production (global capacity ~2 million tons/year as of 2020) but requires substantial hydrogen input, contributing to operational costs of approximately $1,500–2,000 per ton of BDO depending on feedstock prices. Butadiene-based processes, such as the acetoxylation-hydrogenation route developed by companies like Kuraray, provide a third traditional pathway, converting 1,3-butadiene to 3,4-diacetoxy-1-butene via reaction with acetic acid and oxygen over palladium catalysts, followed by hydrolysis and hydrogenation to BDO. Launched commercially in 1982 by Kuraray in Japan, this process offered yields up to 95% and displaced the Reppe monopoly by leveraging abundant C4 streams from petroleum cracking, though it generates acetate byproducts requiring separation. These petrochemical routes collectively dominated BDO supply through the late 20th century, supporting annual global output exceeding 2.5 million tons by the 2010s, primarily for downstream polymers like polytetramethylene terephthalate.

Alternative and Emerging Processes

One prominent alternative to petrochemical routes involves bio-based fermentation processes, where genetically engineered microorganisms convert renewable feedstocks such as glucose or other carbohydrates into 1,4-butanediol (BDO). These methods leverage metabolic engineering to introduce pathways like the succinate or 4-hydroxybutyrate routes in hosts such as Escherichia coli or yeast, achieving titers up to 18 g/L in optimized strains as of 2023. Commercialization efforts, including those by Genomatica in partnership with BASF, have scaled bio-BDO production from sugar feedstocks, with plants operational since the early 2010s and expansions noted through 2025 for applications in bioplastics. A hybrid approach combines bio-derived succinic acid—produced via fermentation of glucose by engineered Basfia succiniciproducens or Escherichia coli—with chemical hydrogenation. Succinic acid is first esterified with methanol to form dimethyl succinate, which is then selectively hydrogenated over copper-based catalysts at 200–250°C and 20–30 bar, yielding BDO at 91.2% selectivity under optimized conditions reported in 2023. This method reduces reliance on fossil feedstocks while utilizing established bio-succinic production, which reached commercial scales exceeding 10,000 tons annually by 2020 from producers like BASF and Reverdia. Emerging microbial platforms extend beyond bacteria to include oleaginous yeasts like Yarrowia lipolytica, engineered with upstream modules for 4-hydroxybutyryl-CoA production and downstream dehydrogenases, achieving de novo BDO synthesis from glucose with improved flux in strains developed as of 2025. Anaerobic pathways in Clostridia species, such as Clostridium acetobutylicum, have also shown promise by redirecting C4 metabolism toward BDO, with genetic modifications blocking competing butanol production to enhance yields up to 5–10 g/L in lab-scale fermentations reported in 2024. These biological routes generally operate under milder conditions (30–40°C, ambient pressure) compared to traditional high-temperature chemical processes, though challenges persist in downstream purification costs and achieving economic parity with petroleum-derived BDO, which dominates over 95% of global supply as of 2025.

Legitimate Industrial Applications

Role in Polymer and Plastic Manufacturing

1,4-Butanediol serves as a key diol monomer in the synthesis of polybutylene terephthalate (PBT), a semicrystalline thermoplastic polyester engineering plastic produced via polycondensation of purified terephthalic acid (PTA) or dimethyl terephthalate (DMT) with 1,4-butanediol. This reaction yields PBT resins valued for their high mechanical strength, dimensional stability, low moisture absorption, and resistance to heat and chemicals, enabling applications in automotive components such as connectors, housings, and under-the-hood parts, as well as in electrical and electronic goods like switches and bobbin cases. Continuous production processes have largely replaced batch methods, improving efficiency in large-scale manufacturing. In polyurethane production, 1,4-butanediol functions primarily as a chain extender, reacting with diisocyanates to form hard segments that enhance the polymer's tensile strength, abrasion resistance, and thermal stability in thermoplastic polyurethane (TPU) elastomers. Urethane-grade 1,4-butanediol, characterized by high purity (>99.5%), low moisture content (<200 ppm), and a boiling point of 235°C, ensures crystalline urethane domains that facilitate melt processing at elevated temperatures while maintaining elastomeric properties at room temperature. These TPUs find use in flexible molded parts, coatings, adhesives, and fibers, with the linear structure of 1,4-butanediol contributing to phase separation between hard and soft segments for optimal performance. Additionally, 1,4-butanediol is dehydrogenated to tetrahydrofuran (THF), which polymerizes to polytetramethylene ether glycol (PTMEG), a polyether diol intermediate for soft segments in high-performance polyurethanes and spandex fibers (elastane). This pathway supports elastic materials with superior stretch recovery and durability, used in textiles, medical devices, and industrial belting. Global 1,4-butanediol demand for such polymer applications drives a significant portion of its approximately 3 million metric tonne annual production capacity as of 2021, with growth tied to engineering plastics and elastomers sectors.

Solvent and Other Industrial Uses

1,4-Butanediol (BDO) functions as an industrial solvent owing to its physical properties, including a high boiling point of 230 °C, low vapor pressure, and minimal odor, which enable effective dissolution without rapid evaporation or strong olfactory impact. Its complete miscibility with water, alcohols, esters, and ketones—coupled with insolubility in aliphatic hydrocarbons—allows it to serve as a polar solvent in formulations requiring compatibility across aqueous and organic phases. These attributes position BDO as suitable for applications demanding stable, non-flammable solvency under moderate temperatures, though its viscosity (approximately 75 mPa·s at 25 °C) may necessitate blending for lower-drag uses. In cleaning and maintenance sectors, BDO is incorporated into formulations for general-purpose cleaners, paint removers, and engine degreasers, where it aids in emulsifying oils, resins, and pigments without aggressive corrosivity. Its low acute toxicity profile—classified under GHS as Category 4 for oral exposure—supports safer handling in occupational settings compared to more volatile hydrocarbons. For instance, in degreasing operations, BDO's ability to penetrate and solubilize greasy deposits enhances efficacy while minimizing environmental release of harsher solvents. Beyond direct solvency, BDO finds utility as a processing aid in adhesive manufacturing and specialty chemical synthesis, where it acts as a reaction medium or diluent to control viscosity and promote uniform mixing. In these roles, its chemical stability under acidic or basic conditions facilitates intermediate steps without unwanted side reactions, contributing to yields in downstream purification. Global demand for such non-polymer applications remains secondary to bulk intermediates but sustains niche markets, with production volumes allocated accordingly in facilities emphasizing high-purity grades (>99.5%).

Economic and Sectoral Impact

The global 1,4-butanediol market was valued at USD 7.8 billion in 2024 and is projected to reach USD 11.1 billion by 2029, reflecting a compound annual growth rate of 7.3%, primarily driven by expanding demand for high-performance polymers in automotive, electronics, and textiles sectors. Production volumes are anticipated to increase from 2.56 million metric tons in 2025 to 3.05 million metric tons by 2030, with Asia-Pacific accounting for over 76% of consumption in 2024, led by China's dominant production capacity exceeding 50% of the global total. This concentration in Chinese output, which reached approximately 62% of worldwide capacity by 2025, exposes supply chains to geopolitical and capacity expansion risks, influencing price volatility in downstream industries. In polymer and plastics manufacturing, 1,4-butanediol functions as a critical monomer for polybutylene terephthalate (PBT), enabling engineering plastics with superior mechanical and thermal properties used in automotive under-the-hood components, electrical connectors, and consumer electronics housings. Its conversion to tetrahydrofuran (THF) supports polytetramethylene ether glycol (PTMEG) production for spandex fibers, bolstering the textile sector's elastic materials market, while incorporation into polybutylene adipate terephthalate (PBAT) aids biodegradable plastics for packaging, aligning with regulatory pushes for reduced plastic waste. These applications contribute to sectoral efficiency gains, as PBT and related resins enhance product durability and lightweighting in vehicles, indirectly supporting fuel efficiency standards and emissions reductions in transportation. Broader economic effects stem from 1,4-butanediol's integration into the petrochemical value chain, where expansions in Asian capacity since 2018 have lowered costs for end-users but heightened dependency on fossil-derived feedstocks like acetylene and maleic anhydride. Emerging bio-based routes, though currently minor at under 5% of output, promise diversification and potential cost stabilization amid volatile oil prices, fostering innovation in sustainable chemical production. Major producers including BASF and DCC, operating facilities across Asia and Europe, sustain thousands of jobs in chemical manufacturing, with the sector's output tying into larger economies where specialty chemicals represent about 34% of U.S. chemical shipments totaling USD 789.2 billion in 2023.

Metabolism and Relation to Gamma-Hydroxybutyric Acid

Biochemical Conversion Pathway

In vivo, 1,4-butanediol undergoes rapid metabolic conversion to γ-hydroxybutyric acid (GHB) primarily in the liver via a two-step enzymatic oxidation process. The initial step involves oxidation to γ-hydroxybutyraldehyde, catalyzed by alcohol dehydrogenase (ADH), which serves as the rate-limiting enzyme in this pathway. This intermediate is then swiftly oxidized to GHB by aldehyde dehydrogenase (ALDH). The overall conversion is efficient, with studies indicating near-complete transformation in human liver microsomes and cytosol, mirroring the ethanol-to-acetaldehyde pathway but yielding GHB as the end product. The biochemical pathway exploits the broad substrate specificity of ADH and ALDH, enzymes typically involved in alcohol detoxification. Inhibition of ADH, as demonstrated by fomepizole in vitro and in rodent models, significantly reduces BDO-derived GHB formation, underscoring the enzyme's pivotal role. Once formed, GHB can either exert central nervous system effects via GABA_B receptor agonism or undergo further catabolism, including conversion to succinic semialdehyde by GHB dehydrogenase (a form of succinic semialdehyde reductase operating in reverse) and subsequent entry into the tricarboxylic acid cycle. However, the primary pharmacological relevance of 1,4-butanediol ingestion stems from its quantitative conversion to GHB, which accounts for the observed sedative and euphoric effects. This metabolic route explains the delayed onset of effects compared to direct GHB administration, as the oxidation steps introduce a pharmacokinetic lag, with peak GHB levels occurring 1-2 hours post-ingestion in animal models. Human pharmacokinetic data, though limited due to ethical constraints, align with these findings from in vitro and preclinical studies.

Pharmaceutical Applications of Derived GHB

Gamma-hydroxybutyric acid (GHB), derived endogenously or via metabolic conversion from precursors like 1,4-butanediol, serves as the active pharmaceutical agent in sodium oxybate formulations for treating narcolepsy symptoms. Sodium oxybate, the sodium salt of GHB, is FDA-approved for reducing cataplexy and excessive daytime sleepiness (EDS) in adults and pediatric patients aged 7 years and older with narcolepsy. The approval for cataplexy was granted on July 17, 2002, under the brand name Xyrem, with orphan drug status due to the rarity of narcolepsy. Subsequent approvals include Xywav, a lower-sodium oxybate salt combination, in 2020 for narcolepsy in adults and idiopathic hypersomnia. The therapeutic mechanism of GHB involves agonism at GABA-B receptors, which enhances slow-wave sleep consolidation and suppresses REM sleep intrusions that contribute to cataplexy. At pharmacological doses, GHB also weakly activates specific GHB receptors, though GABA-B mediation predominates for anti-cataplectic effects. Clinical efficacy stems from improved nocturnal sleep architecture, reducing daytime symptoms without the stimulant side effects of alternatives like modafinil. Administration requires oral solution taken in divided doses: an initial dose at bedtime followed by a second 2.5 to 4 hours later, due to GHB's short half-life of approximately 30-60 minutes. Doses typically start at 4.5 g/night for adults, titrated up to 9 g/night based on response and tolerability. As a Schedule III controlled substance, sodium oxybate is distributed via restricted programs like REMS to mitigate abuse potential, given its structural relation to recreational GHB. Investigational uses have explored GHB for conditions like fibromyalgia and alcohol withdrawal, but lack FDA approval; evidence remains limited to small trials showing modest benefits in sleep quality without broad therapeutic validation. No approved applications exist beyond narcolepsy spectrum disorders, underscoring its niche role despite endogenous presence in mammalian brain at micromolar concentrations.

Effects and Pharmacology

Pharmacokinetics in Humans

1,4-Butanediol is rapidly absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations (Tmax) reached in 24 ± 12 minutes in healthy volunteers given a 25 mg/kg dose. The compound is extensively metabolized in the liver, first by alcohol dehydrogenase to γ-hydroxybutyraldehyde and then by aldehyde dehydrogenase to γ-hydroxybutyric acid (GHB), achieving near-complete conversion as evidenced by superimposable plasma decay curves compared to direct GHB administration.
 The mean elimination half-life of 1,4-butanediol is 39.3 ± 11 minutes under these conditions, with derived GHB exhibiting a half-life of 52 ± 15 minutes. Human data on distribution volume are sparse, though the molecule's polarity suggests equilibration across body water compartments; inhibition studies confirm hepatic predominance in clearance. Excretion occurs mainly via further oxidation of GHB to succinate and entry into the tricarboxylic acid cycle, yielding CO2 as the primary endpoint, with minor renal elimination of metabolites and negligible unchanged drug.

Pharmacodynamics and Physiological Mechanisms

1,4-Butanediol (BDO) exerts its pharmacodynamic effects primarily through rapid metabolic conversion to gamma-hydroxybutyrate (GHB) via alcohol dehydrogenase in the liver, mimicking the actions of exogenous GHB as a central nervous system depressant. This biotransformation results in GHB plasma concentrations that drive the compound's psychoactive and sedative properties, with central effects mediated predominantly by GABA_B receptor activation rather than direct GHB receptor agonism. The GHB receptor antagonist NCS-382 fails to block BDO-induced behaviors such as catalepsy and hypothermia in animal models, whereas GABA_B antagonists like CGP 35348 effectively attenuate these responses, confirming the downstream role of GABA_B signaling. GHB, derived from BDO, functions as a weak agonist at GABA_B receptors (EC50 approximately 1-3 mM) and a high-affinity agonist at specific GHB receptors, though pharmacological effects at typical doses arise mainly from GABA_B receptor stimulation due to higher endogenous GHB levels required for GHB receptor saturation. Activation of presynaptic GABA_B receptors inhibits voltage-gated calcium channels and reduces neurotransmitter release (including glutamate, GABA, and dopamine), while postsynaptic activation opens G-protein inwardly rectifying potassium (GIRK) channels, causing neuronal hyperpolarization and decreased excitability. These mechanisms underlie the dose-dependent CNS depression observed, including sedation, euphoria at low doses (via indirect dopaminergic facilitation in the nucleus accumbens), and respiratory suppression at higher doses. In human studies, oral BDO administration (25 mg/kg) produces subjective effects such as reduced alertness, impaired concentration, and lightheadedness peaking within 90 minutes, accompanied by minor physiological changes like transient systolic/diastolic blood pressure elevations and slight oxygen desaturation (mean 98.5% vs. 99.6% placebo). BDO may possess limited inherent pharmacological actions independent of GHB conversion, potentially related to its diol structure, but these are overshadowed by GHB-mediated effects in vivo. Overall, the pharmacodynamics reflect GHB's bidirectional influence on GABAergic and dopaminergic systems, contributing to both therapeutic potential (e.g., in narcolepsy) and abuse liability through tolerance development at GABA_B sites.

Observed Short-Term Effects

Ingestion of 1,4-butanediol produces short-term effects mediated by its conversion to gamma-hydroxybutyric acid (GHB), with onset typically delayed 15-30 minutes compared to direct GHB administration due to metabolic processing. At low to moderate doses (e.g., 1-3 mL or ~25 mg/kg), observed effects include sedation, mild drowsiness, relaxation, mood elevation, reduced anxiety, lightheadedness, and impaired concentration or alertness, often accompanied by euphoria, warmth, accelerated thought processes, and mild sexual stimulation. These manifestations peak within 30 minutes, featuring muscle relaxation, short-term immobility or oblivion-like sleep, and moderate generalized weakness, with effects generally resolving over 1-1.5 hours. Higher doses escalate central nervous system depression, leading to profound sedation, hypotonia, amnesia, impaired coordination, and potential loss of consciousness or coma. Clinical observations from misuse cases report gastrointestinal disturbances such as vomiting and nausea, alongside autonomic changes including bradycardia, hypotension, transient blood pressure instability, sweating, tremor, and mild fever (38-39°C). Respiratory depression, urinary or fecal incontinence, agitation, combativeness, myoclonus, and labile consciousness levels have also been documented, particularly in overdoses ranging from 5-20 g. Visual distortions and decreased oxygen saturation may occur even at controlled doses. Co-ingestion with alcohol or other depressants amplifies these risks, increasing the likelihood of severe respiratory compromise or seizures.

Recreational Misuse

User Motivations and Patterns of Use

Users recreationally ingest 1,4-butanediol primarily to achieve the pharmacological effects of its rapid metabolic conversion to gamma-hydroxybutyric acid (GHB), which produces euphoria, relaxation, sedation, and mood elevation. These effects are sought for recreational enhancement in social settings, such as parties or clubs, where users report increased self-confidence, sociability, and disinhibition similar to those associated with GHB use. Additional motivations include heightened libido, suggestibility, and perceived sexual stimulation, though these can contribute to its misuse in facilitating non-consensual encounters due to induced passivity and amnesia. Patterns of use typically begin with low oral doses, such as 1 mL of a dilute solution (equivalent to approximately 1 g of pure 1,4-butanediol), administered sporadically for initial euphoric effects. Tolerance develops rapidly after 10–15 exposures, prompting escalation to multiple daily doses—often 3–5 times per day initially, progressing to 20–40 administrations in advanced phases over weeks to months. Consumption occurs via direct ingestion, sometimes diluted in beverages, and is common among experienced polydrug users in nightlife environments, though chronic patterns emerge in dependent individuals, with daily totals reaching 100–150 mL in severe cases. Co-use with alcohol or stimulants heightens risks, as the narrow margin between desired effects and overdose narrows further with repeated exposure.

Dose-Dependent Experiences

Recreational users report that low doses of 1,4-butanediol, typically around 1 mL (approximately 1 g, assuming a density of about 1.02 g/mL), produce mild sedative effects including drowsiness, relaxation, and moderate mood elevation, with possible accompanying nausea or visual distortions. Onset occurs within 5–20 minutes after oral ingestion, particularly faster (7–10 minutes) when taken on an empty stomach, reflecting its rapid metabolic conversion to gamma-hydroxybutyric acid (GHB) via alcohol dehydrogenase. At moderate recreational doses of 1–3 mL (1–3 g), users experience more pronounced euphoria, warmth, increased sociability, and thought or motor acceleration, akin to enhanced disinhibition without severe impairment, though coordination may begin to suffer and short-term sleep episodes can occur. These effects, lasting 2–3 hours overall with peak intensity around 30 minutes, drive its misuse as a GHB alternative for its relaxant and mildly stimulating profile at this range, but individual tolerance develops quickly after 10–15 uses, altering subjective responses toward intensified craving. Higher doses exceeding 3 mL (3 g), often seen in escalation or overdose scenarios up to 14–20 g in reported cases, shift toward heavy sedation, impaired coordination, anterograde amnesia, and potential loss of consciousness, with risks of seizures, respiratory depression, and coma due to excessive GHB accumulation. Such levels amplify depressant mechanisms, leading to diminished euphoria and heightened toxicity, particularly when combined with alcohol, underscoring the narrow therapeutic window in recreational contexts.

Long-Term Consequences and Dependence

Chronic use of 1,4-butanediol (1,4-BD) leads to rapid development of physical and psychological dependence, primarily due to its metabolic conversion to gamma-hydroxybutyric acid (GHB), which acts on GHB receptors and GABA_B receptors in the brain, fostering tolerance and compulsive redosing to avoid withdrawal. Users often escalate doses over time, with reports indicating dependence can emerge within weeks of regular intake, mirroring GHB's high addictive potential observed in clinical and animal studies. Animal models, such as baboons administered chronic 1,4-BD, demonstrate clear physical dependence, with withdrawal severity classified as mild to intermediate, underscoring the substance's reinforcing properties independent of direct GHB administration. Withdrawal from 1,4-BD cessation is characterized by a severe syndrome akin to alcohol or benzodiazepine withdrawal, including autonomic hyperactivity (tachycardia, hypertension, diaphoresis), tremors, anxiety, insomnia, hallucinations, seizures, and delirium, potentially lasting 6 days or more and complicated by rhabdomyolysis or multi-organ failure in extreme cases. Human case series document prolonged withdrawal courses in chronic users, with symptoms emerging rapidly upon abrupt discontinuation and requiring medical detoxification, often with benzodiazepines or baclofen to mitigate risks like refractory seizures. The syndrome's intensity correlates with daily dose and duration of use, with high-dependence individuals facing life-threatening complications without supervised taper. Long-term consequences include potential neurotoxicity and cognitive impairments from repeated GHB-like exposure, as evidenced by rat studies showing deficits in working memory and spatial learning after chronic administration equivalent to recreational doses. Chronic users report persistent psychiatric issues such as depression, anxiety disorders, and cravings, compounded by polysubstance interactions common in recreational contexts. While human longitudinal data are limited due to the illicit nature of misuse, available evidence from GHB-dependent cohorts indicates elevated risks of repeated comas, organ damage, and relapse, with tolerance reversibility observed after abstinence but no guaranteed recovery from cumulative neuronal stress.

Risks and Toxicity

Acute Adverse Effects and Overdose

Ingestion of 1,4-butanediol (BDO) produces acute adverse effects primarily through its rapid metabolism to gamma-hydroxybutyrate (GHB) via alcohol dehydrogenase, resulting in central nervous system (CNS) depression similar to GHB intoxication. Common symptoms include vomiting, drowsiness, vertigo, and hypotonia, often onsetting within 15-30 minutes of oral administration. At moderate doses exceeding recreational thresholds (typically 1-2 grams), users may experience disinhibition, euphoria followed by sedation, and short-term amnesia. In overdose scenarios, generally involving doses above 5 grams, BDO induces profound CNS and respiratory depression, manifesting as bradycardia, hypotension, myoclonus, hypothermia, and loss of consciousness progressing to coma. Clinical reports document agitation, combativeness, urinary and fecal incontinence, areflexia, and miosis in severe cases, with potential for seizures and apnea due to the steep dose-response curve akin to GHB. Animal studies indicate oral LD50 values ranging from 1.2 to 2.5 g/kg body weight across species, underscoring low acute lethality but high risk of respiratory failure as the primary toxic mechanism. Fatal outcomes from BDO overdose have been reported, often involving blood concentrations of BDO or GHB equivalents exceeding 100-200 mg/L, leading to catalepsy, respiratory arrest, and cardiorespiratory collapse without intervention. Case studies highlight solitary ingestions resulting in death, such as a 51-year-old male found deceased post-ingestion, with postmortem analysis confirming BDO as the causative agent. Polydrug interactions, particularly with alcohol or opioids, exacerbate risks by potentiating GABAergic effects and inhibiting BDO metabolism. Supportive management in acute settings focuses on airway protection and ventilation, as no specific antidote exists beyond blocking conversion with alcohol dehydrogenase inhibitors like fomepizole in experimental contexts.

Chronic Health Impacts

Chronic use of 1,4-butanediol (1,4-BD), often through recreational misuse, primarily manifests as the development of physical dependence due to its rapid metabolism into gamma-hydroxybutyric acid (GHB) in the body, mimicking the pharmacological profile of GHB. Tolerance builds with repeated administration, necessitating escalating doses to achieve desired effects, which heightens the risk of adverse outcomes. Dependence is characterized by compulsive use patterns, with users reporting around-the-clock dosing every 1-3 hours to avoid withdrawal, leading to profound disruptions in daily functioning. Abrupt cessation or reduction in chronic 1,4-BD intake precipitates a severe withdrawal syndrome akin to that of GHB, alcohol, or benzodiazepines, involving GABAergic dysregulation. Symptoms typically emerge within 1-6 hours of the last dose and peak at 24-72 hours, including insomnia, extreme anxiety, tremors, diaphoresis, tachycardia, hypertension, confusion, hallucinations, agitation, and psychotic behavior. In severe cases, withdrawal can progress to seizures, delirium, rhabdomyolysis, and life-threatening autonomic instability, often necessitating hospitalization and pharmacological management with benzodiazepines or barbiturates. The syndrome's intensity correlates with daily dose and duration of use, with documented fatalities attributed to unmanaged withdrawal complications such as cardiac arrest or respiratory failure. Beyond dependence and withdrawal, data on other long-term health impacts in humans remain limited, with most evidence extrapolated from GHB studies or short-term animal models. Repeated high-dose exposure may contribute to neurotoxicity, potentially from recurrent episodes of coma-like sedation, raising concerns for cognitive deficits, memory impairment, and persistent anxiety, though prospective human studies are lacking. No conclusive evidence links chronic 1,4-BD use to specific organ toxicities like hepatotoxicity or carcinogenicity in humans, but the compound's role as a GHB precursor underscores risks of cardiovascular strain from autonomic effects during chronic intoxication cycles. 1,4-Butanediol (BDO) demonstrates acute oral toxicity comparable to its primary metabolite, gamma-hydroxybutyric acid (GHB), and the related prodrug gamma-butyrolactone (GBL), with all three compounds exhibiting low to moderate lethality in rodent models primarily through central nervous system depression and respiratory failure. The oral LD50 for BDO in rats ranges from 1.525 to 2.00 g/kg, reflecting catalepsy, histopathological liver changes, and delayed mortality. Similarly, GHB's oral LD50 in rats is 1.75 g/kg, while GBL's is 1.54 g/kg, indicating overlapping lethal thresholds driven by GHB-mediated effects once BDO or GBL is endogenously converted. Despite similar LD50 values, BDO's toxicity is less immediate and potent per milligram due to its stepwise enzymatic conversion to GHB via alcohol dehydrogenase and aldehyde dehydrogenase, requiring higher ingested doses (often 1.5–2 times equivalent GHB amounts) for comparable peak plasma GHB levels, which introduces variability from individual metabolic rates but maintains a narrow safety margin akin to GHB's 5:1 to 8:1 ratio between recreational and fatal doses. Co-ingestion with ethanol exacerbates BDO's lethality by competitively inhibiting its metabolism, elevating tissue damage and mortality rates in rats.
SubstanceOral LD50 (rats, g/kg)Primary Toxic Mechanism
1,4-Butanediol1.5–2.0GHB-mediated CNS/respiratory depression
GHB1.75Direct CNS depression, narrow index
GBL1.54Rapid hydrolysis to GHB
Ethanol~7.0CNS depression, less potent acutely (contextual comparison)
In contrast to ethylene glycol, a structurally related diol with an oral LD50 of approximately 4.7 g/kg in rats, BDO lacks the severe renal toxicity from oxalate metabolites, instead mimicking toxic alcohol acidosis (high anion gap metabolic acidosis) transiently via GHB but resolving without oxalate-induced organ failure upon supportive care. This differentiates BDO's profile from other glycols like 1,2-propanediol, which shows lower acute toxicity (LD50 >20 g/kg) and minimal CNS effects, underscoring BDO's unique risks tied to GHB pharmacodynamics rather than direct glycol metabolism.

Notable Incidents

Product Contamination Events

In November 2007, the children's craft toy Aqua Dots (known as Bindeez in Australia and the United Kingdom) was subject to a widespread recall after analysis revealed that its adhesive beads contained approximately 14% extractable 1,4-butanediol by weight, substituted for the intended non-toxic 1,5-pentanediol. This manufacturing error, traced to a Chinese supplier using the cheaper industrial chemical, led to accidental ingestions by children mistaking the beads for candy, triggering metabolic conversion to gamma-hydroxybutyrate (GHB) and subsequent toxic effects. The U.S. Consumer Product Safety Commission (CPSC) initiated a voluntary recall of about 11 million units on November 7, 2007, following reports of children experiencing unconsciousness, respiratory depression, seizures, vomiting, ataxia, and coma after swallowing beads. In the United States, the CPSC documented at least two cases of unconsciousness directly linked to the product. Australian authorities reported multiple hospitalizations, including a confirmed case in a 7-year-old girl who ingested beads from a Bindeez set, presenting with acute drowsiness, vomiting, hypotonia, and bradypnea; laboratory analysis detected GHB in her system, with toy beads testing positive for 1,4-butanediol. Another Australian incident involved a child in prolonged coma, prompting national alerts from the Poisons Information Centre. Similar recalls occurred in Canada, Europe, and elsewhere, affecting over 500,000 units in the UK alone, though no Canadian illnesses were reported at the time. The事件 resulted in regulatory scrutiny and a 2011 CPSC civil penalty of $1.3 million against distributor Spin Master for delayed reporting and distribution of the hazardous product. Symptoms from documented ingestions of several dozen beads aligned with GHB-like intoxication, including self-limited coma, but resolved without long-term sequelae in reported survivors; no fatalities were directly attributed. This incident remains the most prominent example of 1,4-butanediol contamination in consumer goods, emphasizing supply chain vulnerabilities in global manufacturing rather than deliberate adulteration.

Documented Poisonings and Fatalities

From April 1998 to April 1999, the U.S. Food and Drug Administration received 119 reports of adverse events associated with 1,4-butanediol ingestion marketed as a dietary supplement, including two fatalities. The deaths involved doses ranging from 5.4 to 20 grams, with no co-ingested intoxicants identified in postmortem analyses; symptoms prior to death included coma, respiratory depression, and bradycardia, consistent with gamma-hydroxybutyrate (GHB) toxicity following metabolic conversion of 1,4-butanediol. Nonfatal cases in the same period involved doses of 1 to 14 grams and required interventions such as intubation in 19 patients and mechanical ventilation in 9. A 2001 New England Journal of Medicine study detailed nine toxic episodes from 1,4-butanediol ingestion between June and December 1999, including two deaths associated with products like Thunder Nectar, which contained 1,4-butanediol and were marketed as dietary supplements for effects such as libido enhancement and muscle growth; these incidents involved serious adverse effects including vomiting, unconsciousness, respiratory depression, and coma. One case involved a healthy 32-year-old man who ingested approximately 200 ml of Thunder Nectar, resulting in fatality from respiratory depression and pulmonary edema, while his wife survived after experiencing unconsciousness. Sellers of such products ceased marketing them due to legal pressure, seizures, and liability risks following these adverse events; by the early 2000s, 1,4-butanediol and similar precursors became heavily regulated or illegal for human consumption under U.S. federal law, often treated similarly to GHB, leading to their disappearance from legal markets. A fatal intoxication was reported in 2022 involving a 51-year-old man found unresponsive in his residence after intentional oral ingestion of 1,4-butanediol obtained online. Postmortem toxicology detected 140 mg/L of 1,4-butanediol and 190 mg/L of GHB in femoral blood, with the cause of death attributed to GHB intoxication leading to cerebral edema and multi-organ failure, excluding alternative etiologies such as trauma or other substances. This case underscores the narrow therapeutic index of 1,4-butanediol, where rapid conversion to GHB precipitates lethal respiratory and central nervous system depression. Literature reviews indicate additional isolated fatalities linked to 1,4-butanediol misuse, often in polysubstance contexts or as a GHB surrogate, though specific case documentation remains sparse due to analytical challenges in distinguishing it from endogenous GHB levels postmortem. Acute poisonings typically manifest as GHB-like effects including unconsciousness, seizures, and renal impairment, with lethality thresholds estimated at blood GHB equivalents exceeding 100-200 mg/L from precursor ingestion. No large-scale epidemiological data exist solely for 1,4-butanediol, as many incidents are reported under broader GHB analogue categories by poison control centers.

International Controls as GHB Precursor

1,4-Butanediol is not included in Table I or Table II of precursors under the 1988 United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, which mandates controls on specific chemicals essential for illicit drug production. Similarly, it is absent from schedules of the 1971 United Nations Convention on Psychotropic Substances, where gamma-hydroxybutyrate (GHB) itself is listed in Schedule IV. The International Narcotics Control Board (INCB), tasked with monitoring compliance with UN drug conventions, classifies 1,4-butanediol as a pre-precursor to gamma-butyrolactone (GBL), which in turn serves as a direct precursor to GHB, noting its frequent diversion for illicit conversion due to endogenous metabolism into GHB upon ingestion. In 2015, following a World Health Organization (WHO) Expert Committee on Drug Dependence review, the UN Commission on Narcotic Drugs decided against adding 1,4-butanediol or GBL to Schedule I of the 1971 Convention, citing insufficient evidence of widespread international abuse patterns warranting global scheduling despite acknowledged risks as GHB substitutes. The INCB has since emphasized voluntary international cooperation on non-scheduled pre-precursors like 1,4-butanediol, reporting annual seizures—such as over 10 metric tons globally in some years—and urging governments to implement export/import notifications, pre-export declarations, and end-user verifications to prevent diversion, particularly from legitimate industrial uses in solvents and polymers. This monitoring framework reflects causal links between unregulated trade in 1,4-butanediol and GHB-related harms, including overdoses, but lacks binding international licensing or quota requirements applicable to scheduled precursors like those for amphetamine production. INCB annual reports highlight patterns of clandestine importation, often via small consignments misdeclared as industrial cleaners, underscoring the need for enhanced global intelligence-sharing without formal controls.

Country-Specific Regulations and Enforcement

In the United States, 1,4-butanediol is regulated federally as a List I chemical under the Drug Enforcement Administration (DEA), requiring reporting of imports, exports, and certain domestic transactions due to its role as a precursor in gamma-hydroxybutyrate (GHB) production. It is not scheduled as a controlled substance under the Controlled Substances Act, though the Food and Drug Administration classified it as a Class I health hazard on March 13, 2000, citing risks of severe adverse effects. State-level controls vary; for instance, Florida statutes exempt certain industrial formulations but prohibit sales implying human consumption or easy extraction for GHB synthesis. Enforcement emphasizes diversion prevention, with DEA operations targeting unregulated sales, such as a 2004 St. Louis case involving bulk shipments disguised as industrial cleaners, leading to arrests for precursor trafficking. In Canada, 1,4-butanediol is designated a Schedule VI precursor under the Controlled Drugs and Substances Act, subjecting it to import/export licensing, record-keeping, and declaration requirements administered by Health Canada. Exemptions apply to formulated products like fragrances or silicones where extraction is not feasible, but standalone sales for potential GHB conversion are restricted. Enforcement involves Canada Border Services Agency (CBSA) interdictions, including a March 2025 seizure of 400 liters at Vancouver, and a May 2025 seizure of 3,600 liters intercepted from China at the Tsawwassen facility (announced October 2025), aimed at blocking recreational misuse despite its non-scheduled drug status domestically. Australia classifies 1,4-butanediol as a border controlled precursor under the Criminal Code, prohibiting unlicensed importation with penalties up to life imprisonment for large quantities, reflecting its scheduling in the Standard for the Uniform Scheduling of Drugs and Poisons. The Australian Federal Police (AFP) and Border Force (ABF) have intensified enforcement against "bute" imports, seizing over 3.8 tonnes in the first half of 2025 alone, often concealed in consumer goods. Notable actions include an August 2024 Queensland prosecution for 60 liters imported via mail, highlighting joint operations disrupting organized syndicates. In the United Kingdom, 1,4-butanediol faced temporary scheduling as a Class B drug under the Misuse of Drugs Act via addition to Schedule 1 of the 2001 Regulations in 2021, but this was revoked on June 14, 2022, reverting to precursor monitoring without possession criminalization for personal use. Industrial supply remains legal with oversight, though sales implying human consumption trigger scrutiny under existing GHB controls. Enforcement focuses on supply chains, informed by 2009 Home Office reports on its GHB prodrug conversion. Across the European Union, 1,4-butanediol lacks uniform drug scheduling but is monitored as a GHB precursor under Council Regulation (EC) No 273/2004, requiring vigilance by member states for diversion risks. France's ANSES proposed a REACH restriction in 2019 to ban public sales, citing metabolic conversion to GHB, though implementation varies by country. Enforcement emphasizes cross-border alerts via Europol, with limited national bans allowing industrial access while curbing online retail for misuse. 1,4-Butanediol undergoes dehydrogenation to produce γ-butyrolactone (GBL), a key intermediate used in the synthesis of pyrrolidones, herbicides, and pharmaceuticals. This conversion typically occurs under catalytic conditions, such as gas-phase dehydrogenation at temperatures between 150–300 °C. Dehydration of 1,4-butanediol yields tetrahydrofuran (THF), an aprotic solvent essential for Grignard reactions, polymerizations, and extractions in organic synthesis. These transformations highlight 1,4-butanediol's role as a platform chemical in industrial processes. In polymer applications, 1,4-butanediol acts as a diol monomer in condensation reactions to form polybutylene terephthalate (PBT) when combined with terephthalic acid or dimethyl terephthalate, resulting in a semicrystalline thermoplastic with high mechanical strength and heat resistance used in automotive and electronic components. It also serves as a chain extender in polyurethane formulations, contributing to flexible foams and elastomers. Related compounds include γ-hydroxybutyric acid (GHB), formed endogenously from 1,4-butanediol via oxidation by alcohol dehydrogenase to 4-hydroxybutanal, followed by further metabolism; this pathway underlies its pharmacological effects and toxicity profile. Other structural analogs are the isomeric butanediols—1,2-butanediol, 1,3-butanediol, and 2,3-butanediol—which differ in hydroxyl group positioning and exhibit varied applications, such as in antifreeze or biofuels. Succinic acid and succinaldehyde represent oxidation products or precursors in related metabolic or synthetic pathways.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/1_4-Butanediol
  2. https://www.sciencedirect.com/topics/medicine-and-dentistry/butanediol
  3. https://www.epa.gov/greenchemistry/presidential-green-chemistry-challenge-2011-greener-synthetic-pathways-award
  4. https://www.chemicalbook.com/article/1-4-butanediol-uses-and-chemical-property.htm
  5. https://pubmed.ncbi.nlm.nih.gov/17192771/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC6465153/
  7. https://www.deadiversion.usdoj.gov/drug_chem_info/bdo.pdf
  8. https://ntp.niehs.nih.gov/sites/default/files/ntp/htdocs/st_rpts/tox054.pdf
  9. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4452184.htm
  10. https://webbook.nist.gov/cgi/cbook.cgi?ID=110-63-4
  11. https://www.inchem.org/documents/icsc/icsc/eics1104.htm
  12. https://www.welinkschem.com/what-is-bdo-and-what-are-its-characteristics/
  13. https://www.dcc.com.tw/ccpprdt.nsf/0/A8E3261E0E877A6B48257ED70024948A/%24FILE/BDO%2520TDS.pdf
  14. https://www.univarsolutions.com/1-4-butanediol-3059035
  15. https://cameochemicals.noaa.gov/chemical/8344
  16. https://www.sciencedirect.com/science/article/abs/pii/S0926860X02005288
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC6651349/
  18. https://pubs.acs.org/doi/10.1021/jo061017o
  19. https://patents.google.com/patent/US5955620A/en
  20. https://pubs.rsc.org/en/content/articlelanding/2019/nj/c9nj03067k
  21. https://www.sciencedirect.com/science/article/pii/S1004954110602364
  22. https://www.tandfonline.com/doi/abs/10.1080/00986440008912193
  23. https://www.gantrade.com/blog/5-key-facts-1-4-butanediol
  24. https://pubs.acs.org/doi/10.1021/acssuschemeng.4c10409
  25. https://www.sciencedirect.com/science/article/pii/S0032386125004057
  26. https://www.acs.org/molecule-of-the-week/archive/b/berkelocene.html
  27. https://jasonresearchchemicals.com/product/14-butanediol/
  28. https://www.osti.gov/etdeweb/servlets/purl/22176040/1000
  29. https://www.chemicalbook.com/article/a-brief-description-of-1-4-butanediol-synthesis-method.htm
  30. https://www.sciencedirect.com/topics/chemistry/butane-1-4-diol
  31. https://ecoquery.ecoinvent.org/3.10/apos/dataset/1014/lci
  32. https://onlinelibrary.wiley.com/doi/10.1002/bbb.2016
  33. https://www.sciencedirect.com/science/article/abs/pii/S0360319925001211
  34. https://www.mordorintelligence.com/industry-reports/1-4-butanediol-market
  35. https://www.marketreportsworld.com/market-reports/1-4-butanediol-market-14715201
  36. https://www.marketgrowthreports.com/market-reports/1-4-butanediol-bdo-market-105466
  37. https://www.mordorintelligence.com/industry-reports/1-4-butanediol-market/companies
  38. https://www.marketsandmarkets.com/ResearchInsight/1-4-butanediol-market.asp
  39. https://www.chemanalyst.com/industry-report/butanediol-market-657
  40. https://www.grandviewresearch.com/industry-analysis/1-4-butanediol-market
  41. https://www.futuremarketinsights.com/reports/14-butanediol-market
  42. https://www.mordorintelligence.com/industry-reports/bio-based-1-4-butanediol-market
  43. https://www.price-watch.ai/14-butanediol-prices/
  44. https://www.procurementresource.com/resource-center/1-4-butanediol-1-4-bd-price-trends
  45. https://www.basf.com/us/en/media/market-news-/2025/BASF-to-increase-its-price-for-select-diols-and-derivatives-in-the-United-States-and-Canada
  46. https://www.industryresearch.biz/market-reports/1-4-butanediol-market-103630
  47. https://www.grandviewresearch.com/horizon/outlook/14-butanediol-market-size/global
  48. https://cdn.intratec.us/docs/reports/previews/butanediol-e31a-b.pdf
  49. https://www.chemanalyst.com/NewsAndDeals/NewsDetails/breaking-down-the-reactor-the-industrial-production-process-of-1-4-butanediol-bdo-38462
  50. https://cdn.intratec.us/docs/reports/previews/butanediol-e61a-b.pdf
  51. https://www.sciencedirect.com/science/article/abs/pii/S0960148124016914
  52. https://2024.sci-hub.se/5903/b19172beaa69c045ace11801b8ca3b4b/izawa2016.pdf
  53. https://www.sciencedirect.com/science/article/pii/S0167779923000240
  54. https://www.chemengonline.com/bio-butanediol-production-glucose/
  55. https://www.chemanalyst.com/NewsAndDeals/NewsDetails/butanediol-bdo-at-the-core-a-deep-dive-into-its-cross-sector-industrial-application-38459
  56. https://pubs.rsc.org/en/content/articlelanding/2023/gc/d2gc03990g
  57. https://pubs.acs.org/doi/pdf/10.1021/acssynbio.5c00015?ref=article_openPDF
  58. https://www.tandfonline.com/doi/full/10.1080/13102818.2024.2415039
  59. https://pubmed.ncbi.nlm.nih.gov/37286203/
  60. https://www.sciencedirect.com/science/article/abs/pii/S0958166916301240
  61. https://www.phite.com/pbt-production-process
  62. https://www.m-chemical.co.jp/en/petrochem-license/technologies/pdf/Introduction_MCC_PBT_Process.pdf
  63. https://www.gantrade.com/blog/characteristics-that-set-urethane-grade-14-butanediol-bdo-apart
  64. https://www.lyondellbasell.com/globalassets/lyb/our-solutions/products/documents/chemicals-technical-literature/bdo-datasheet-2659.pdf
  65. https://www.chemanalyst.com/industry-report/1-4-butanediol-market-542
  66. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/butanediol
  67. https://www.industrialchemicals.gov.au/sites/default/files/1-4-Butanediol.pdf
  68. https://www.marketsandmarkets.com/Market-Reports/1-4-butanediol-market-685.html
  69. https://prismaneconsulting.com/report-details/global-butanediol-market-study
  70. https://www.bloomtechz.com/info/how-is-1-4-butanediol-used-in-the-production-o-102753979.html
  71. https://www.sciencedirect.com/science/article/pii/S0960308524000117
  72. http://www.researchinchina.com/Htmls/Report/2019/11600.html
  73. https://www.emergenresearch.com/industry-report/14-butanediol-market/regional-market-demand?srsltid=AfmBOorf1kT8JdMhLIPIyDe5NhztSQgtpW4m4z8nyuaFPBCCRhG-4uic
  74. https://www.ijpsonline.com/articles/progress-on-the-biological-metabolic-pathways-and-biomarkers-of-gammahydroxybutyric-acid-emin-vivoem-5357.html
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC8098080/
  76. https://www.nejm.org/doi/full/10.1056/NEJM200101113440202
  77. https://pubmed.ncbi.nlm.nih.gov/12063087/
  78. https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1306
  79. https://www.ncbi.nlm.nih.gov/books/NBK562283/
  80. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-fda-approval-xyremr-sodium
  81. https://www.drugs.com/history/lumryz.html
  82. https://www.drugs.com/history/xywav.html
  83. https://go.drugbank.com/drugs/DB09072
  84. https://www.jneurosci.org/content/34/19/6485
  85. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-generic-xyrem-rems-program
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC11950157/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC10698855/
  88. https://www.industrialchemicals.gov.au/sites/default/files/1%252C4-Butanediol_Human%2520health%2520tier%2520II%2520assessment.pdf
  89. https://pubmed.ncbi.nlm.nih.gov/11313294/
  90. https://karger.com/nps/article/73/2/65/233800/The-Neurobiological-Mechanisms-of-Gamma
  91. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1038/sj.clpt.6100037
  92. https://go.drugbank.com/articles/A2583
  93. https://pubmed.ncbi.nlm.nih.gov/11150358/
  94. https://www.sciencedirect.com/science/article/pii/S0955395921001353
  95. https://www.dea.gov/sites/default/files/2020-06/GHB-2020_0.pdf
  96. https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-025-01152-9
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC8843350/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC3718862/
  99. https://pubmed.ncbi.nlm.nih.gov/18226321/
  100. https://www.uptodate.com/contents/gamma-hydroxybutyrate-ghb-withdrawal-and-dependence/abstract/1-13
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC10590033/
  102. https://academic.oup.com/ijnp/article/12/9/1165/666546
  103. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2020.00166/full
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC6103637/
  105. https://pubmed.ncbi.nlm.nih.gov/12074936/
  106. https://pubmed.ncbi.nlm.nih.gov/22746383/
  107. https://onlinelibrary.wiley.com/doi/10.1111/1556-4029.15294
  108. https://hpvchemicals.oecd.org/ui/handler.axd?id=eb88b00e-80ab-43b2-bea0-ea40fb023e17
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC5610436/
  110. https://www.sciencedirect.com/science/article/abs/pii/S0149763412000206
  111. https://pubmed.ncbi.nlm.nih.gov/2134324/
  112. https://www.chemicalbook.com/article/toxicity-of-1-4-butanediol-and-its-treatment.htm
  113. https://pubchem.ncbi.nlm.nih.gov/compound/Gamma-Butyrolactone
  114. https://www.sciencedirect.com/science/article/pii/S0376871623011894
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC4462042/
  116. https://pubmed.ncbi.nlm.nih.gov/3911807/
  117. https://pubmed.ncbi.nlm.nih.gov/31218892/
  118. https://pubmed.ncbi.nlm.nih.gov/19655283/
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC3550398/
  120. https://cen.acs.org/articles/85/web/2007/11/Industrial-Chemical-Sullies-Popular-Childrens.html
  121. https://www.cpsc.gov/Recalls/2007/spin-master-recalls-aqua-dots-children-became-unconscious-after-swallowing-beads
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC2206298/
  123. https://www.mja.com.au/journal/2008/188/1/g-hydroxybutyrate-poisoning-toy-beads
  124. https://www.cbc.ca/news/7-more-children-fall-ill-after-ingesting-aqua-dots-beads-1.655289
  125. https://www.cpsc.gov/Newsroom/News-Releases/2012/in-Master-Agrees-to-13-Million-Civil-Penalty-for-Failing-to-Report-Aqua-Dots-and-for-Selling-a-Banned-Hazardous-Substance
  126. https://digitalcommons.kennesaw.edu/cgi/viewcontent.cgi?article=4710&context=facpubs
  127. https://www.deadiversion.usdoj.gov/21cfr/cfr/1310/1310_02.htm
  128. https://www.incb.org/documents/PRECURSORS/TECHNICAL_REPORTS/2024/E/PRE_Report_E.pdf
  129. https://www.incb.org/documents/PRECURSORS/TECHNICAL_REPORTS/2020/E/Precursors_2020_E_with_annex_Ebook.pdf
  130. https://docs.un.org/en/E/2015/28
  131. https://www.incb.org/documents/PRECURSORS/TECHNICAL_REPORTS/2017/E_ebook_with_annexes.pdf
  132. https://unis.unvienna.org/unis/uploads/documents/2024-INCB/E_INCB2023_Precursors.pdf
  133. https://www.incb.org/documents/Publications/AnnualReports/AR2022/Precursors_Report/E_INCB_2022_4_eng.pdf
  134. https://www.deadiversion.usdoj.gov/drug_chem_info/drug-chem-info.html
  135. https://www.federalregister.gov/documents/2000/03/13/00-5925/schedules-of-controlled-substances-addition-of-gamma-hydroxybutyric-acid-to-schedule-i
  136. https://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0800-0899/0893/Sections/0893.031.html
  137. https://www.dea.gov/sites/default/files/pubs/states/newsrel/stlouis013004.html
  138. https://laws-lois.justice.gc.ca/eng/acts/c-38.8/page-14.html
  139. https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/precursor-chemicals/regulatory-requirements-under-controlled-drugs-substances-act-precursor-control-regulations-international.html
  140. https://www.facebook.com/CanBorder/posts/cbsa-officers-in-vancouver-prevented-400-litres-of-14-butanediol-from-reaching-c/1066406192181806/
  141. https://www.canada.ca/en/border-services-agency/news/2025/10/cbsa-seizes-hundreds-of-litres-of-precursor-chemicals-from-china-used-to-produce-fentanyl.html
  142. https://www.abf.gov.au/newsroom-subsite/Pages/Authorities-warn-over-rise-in-%25E2%2580%2598fantasy%25E2%2580%2599-drug-imports.aspx
  143. https://www.abf.gov.au/newsroom-subsite/Pages/Queensland-man-charged-following-investigation-into-bute-imports.aspx
  144. https://www.gov.uk/government/publications/circular-0042022-gamma-butyrolactone-gbl-and-14-butanediol-14-bd-revocation-of-rescheduling
  145. https://assets.publishing.service.gov.uk/media/5a7ac39940f0b66a2fc02a4c/report-on-gbl1.pdf
  146. https://www.euda.europa.eu/system/files/publications/505/TP_GHB_and_GBL_107300.pdf
  147. http://www.anses.fr/en/content/anses-proposes-undertaking-restriction-procedure-gamma-butyrolactone-and-14-butanediol
  148. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:52000DC0737%2802%29
  149. https://patents.google.com/patent/KR101063772B1/en
  150. https://pubs.rsc.org/en/content/getauthorversionpdf/c8gc00574e
  151. https://www.petrochemistry.eu/sector-group/bdo-derivatives/
  152. https://products.basf.com/global/en/ci/1-4-butanediol
  153. https://www.ashland.com/industries/performance-specialties/intermediates/bdo--1-4-butanediol
  154. https://atamankimya.com/sayfalar.asp?LanguageID=2&cid=3&id=11&id2=3385
Add your contribution
Related Hubs
User Avatar
No comments yet.